Featured Editorial
-
Prince Of Spray Drying Returns As Earl Of Dispersion
12/7/2022
Tim Scott traces the arc of spray drying from its advent to today’s advanced amorphous dispersion technology. Now he's back at it again, pushing the technology to even higher levels of accessibility and productivity.
-
A Methodology To Support Particle Investigations In Biopharma Products
11/22/2022
Particles in parenteral products are a major cause of product recalls, and appropriate management of risk from visible particles is vital. This standardized methodology provides users with a decision-making tool to clarify the risks presented by a particle to a batch.
-
FDA Releases Guidance On Drug Products Containing Nanomaterials
11/18/2022
In the FDA guidance entitled Drug Products, Including Biological Products, that Contain Nanomaterials, “nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.
-
The Upper Nasal Space: Drug Delivery's Next Frontier
11/9/2022
Oral formulations of drugs account for up to 75% of prescriptions. However, many diseases require therapies to provide a maximal benefit as quickly as possible, and oral delivery may result in slow absorption. Enter drug delivery via the upper nasal space, which has the potential to provide a more rapid onset of activity, avoid degradation in the GI tract, and more benefits.
-
Pharma 4.0 Software Methodologies In Biopharma And Medical Devices
10/10/2022
The life sciences industry has been using computer software testing methodology to validate software that is categorized to be GxP in alignment with the principles of good automated manufacturing practices and Industry 4.0 standards. This article discusses the methodologies of computerized system validation, computer software assurance, and the Agile approach.
-
A Practical Guide To Navigate The EU's Revised GMP Annex 1
9/9/2022
The EU's final version of the GMP Annex 1 is now published, and it's time to take action. This article shares a road map to navigate what is new and different, how to document your "known unknowns," and more. Quality risk management and a contamination control strategy will be key.
-
A Star Is Born To Deliver Drugs: Can It Be Outsourced?
8/15/2022
A miniature manmade “star” – with round middle and triangular arms – collapses to fit into a capsule and provides patients an oral drug. The creators of this device-like drug are devoted to production through continuous manufacturing. Can the company also outsource some of what they've developed internally?
-
Assessing Extractables & Leachables In Parenteral Drug Products
6/8/2022
Therapeutic complexity increases the potential risks associated with chemical composition of materials used for drug packaging. Leachables in drug or biological products are chemical compounds that originate from components that are used to store and deliver medicines. Extractables should be considered as potential leachables.
-
CGT Delivery Challenges
5/27/2022
Mass General Brigham recently revealed its “Disruptive Dozen,” 12 emerging cell and gene therapy (CGT) technologies with the greatest potential to impact health care in the next several years. The “Disruptive Dozen” results from interviews of 50 Mass General Brigham senior Harvard faculty followed by a rigorous selection process to identify the 12 most likely to have significant impact on patient care in the next few years.
-
FDA Releases Pre-Launch Activities Importation Requests (PLAIR) Guidance
5/24/2022
The FDA has finalized the draft guidance describing the policy regarding requests for the importation of unapproved finished dosage form drug products by applicants preparing products for U.S. market launch based on anticipated approval of a pending NDA, ANDA, BLA, or combination product assigned to CDER.